How Jim Tananbaum is Assisting Patients of Mental Disorders
Mindstrong’s Health raised $14 million in Series A round, from their Neurological-focused device collections. The money is meant to support and finance its diagnostic platforms and neuropsychiatric treatments. The objective measures of brain function will be measured by the interactive Smartphone device, which has been designed under the Mindstrong’s Al-Powered platform.
The Foresite Capital firm led the Series A round in collaboration with ARCH Ventures, later to be joined by Optum Ventures, Berggruen Holdings, and Brain Health Impact. The new diagnostic criteria being tested is meant to provide digitalized biomarkers of intelligence, cognition, and even mood. It will cater for all the aspects including speed, memory capacity, executive function and even attention.
Why Mindstrong stands out from the rest
Mindstrong’s Health has demonstrated an unmatched understanding of the most critical challenges in the medical community affecting patients with cognitive disorders. The team, therefore, made up of Rick, Paul and Tom brought together their experiences, technical vision, and leadership, to improve the patient outcomes. Mindstrong co-founder, Dr. Tom Insel states that smartphones contain the potential global solutions to these psychiatric problems. The technology aims at delivering a continuous cognition at a level of resolution and insight in a manner that has never been possible before in the medical field. Visit LinkedIn for more info.
Insights into this man Jim Tananbaum
Jim Tananbaum is the Founder of the Foresite Capital Firm and a long standing leader in the healthcare industry, with over 25 years’ experience. His focus is on the financial opportunities, strategy and operational solutions from the modern technologies. Before this, he had co-founded the GelTex Pharmaceuticals, immediately upon leaving Harvard University Medical School. Check out Patiently Daily for the details.
The other principal investment experience of Jim includes being the founding partner of Prospect Venture Partners II and III. He was also a partner at Sierra Ventures as well as many other investments like Amira Pharmaceuticals, Amerigroup and Jazz Pharmaceuticals. Foresite Capital, therefore, was the crowning of all his other experiences in new investment. Jim Tananbaum attended Yale University and graduated with a Bachelor of Science and a B.S.E.E as well as a Master’s Degree and an M.B.A from Harvard Business School. He has served in many capacities including advisory boards and visiting committees at the Harvard-MIT Program and Yale’s Presidential Advisory Council. You can search him on Google for more.
Check out officialjimtananbaum.com